foundational preclinical data for blu-945 showing robust anti-tumor activity
Published 3 years ago • 280 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
3:29
pre-clinical data for novel egfr inhibitor bdtx-1535
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
1:01
dr. heymach on nivolumab for lung cancer
-
0:54
lung cancer can now be treated by a tablet called osimertinib, tagrisso. part 3 #cancer
-
8:47
study of 693 nsclc patients treated with afatinib
-
20:24
targeted treatment with egfr tkis: front line options
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
1:00
lung cancer can now be treated by a tablet called osimertinib, tagrisso. part 1 #cancer
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
0:59
managing amivantamab infusion reaction #2023 #oncology #lungcancer
-
0:18
the #innovate trial is for patients with node-positive #prostatecancer.
-
1:50
researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam
-
1:20
alex spira, md, phd, facp, discusses the mechanism of action of amivantamab (jnj-6372)
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
45:19
mutation based resistance to tki therapy - by frank g. haluska, md, phd
-
2:31
new requirements for laboratories in the immuno-oncology era
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know